CN117337285A - 血红蛋白之调节剂的固体形式 - Google Patents

血红蛋白之调节剂的固体形式 Download PDF

Info

Publication number
CN117337285A
CN117337285A CN202280035091.5A CN202280035091A CN117337285A CN 117337285 A CN117337285 A CN 117337285A CN 202280035091 A CN202280035091 A CN 202280035091A CN 117337285 A CN117337285 A CN 117337285A
Authority
CN
China
Prior art keywords
compound
crystalline
acid
dsc
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280035091.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·D·帕伦特
T·L·休斯顿
C·S·约翰逊
F·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Blood Therapeutics Inc
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of CN117337285A publication Critical patent/CN117337285A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CN202280035091.5A 2021-05-14 2022-05-13 血红蛋白之调节剂的固体形式 Pending CN117337285A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188833P 2021-05-14 2021-05-14
US63/188,833 2021-05-14
PCT/US2022/029289 WO2022241278A1 (en) 2021-05-14 2022-05-13 Solid forms of a modulator of hemoglobin

Publications (1)

Publication Number Publication Date
CN117337285A true CN117337285A (zh) 2024-01-02

Family

ID=82020064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280035091.5A Pending CN117337285A (zh) 2021-05-14 2022-05-13 血红蛋白之调节剂的固体形式

Country Status (13)

Country Link
US (2) US11851424B2 (https=)
EP (1) EP4337659A1 (https=)
JP (1) JP2024520897A (https=)
KR (1) KR20240008356A (https=)
CN (1) CN117337285A (https=)
AR (1) AR126649A1 (https=)
AU (1) AU2022273787B2 (https=)
BR (1) BR112023021606A2 (https=)
CA (1) CA3219786A1 (https=)
MX (1) MX2023012156A (https=)
TW (1) TW202311254A (https=)
WO (1) WO2022241278A1 (https=)
ZA (1) ZA202309517B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250041312A1 (en) * 2021-12-10 2025-02-06 Global Blood Therapeutics, Inc. Methods of administering a modulator of hemoglobin
TW202515579A (zh) * 2023-06-13 2025-04-16 美商全球血液治療公司 投予血紅素的調節劑之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160083343A1 (en) * 2013-03-15 2016-03-24 Global Blood Therapeutics, Inc Compounds and uses thereof for the modulation of hemoglobin
US20200157085A1 (en) * 2018-11-19 2020-05-21 Global Blood Therapeutics, Inc. Modulators of hemoglobin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
WO2022241286A1 (en) * 2021-05-14 2022-11-17 Global Blood Therapeutics, Inc. Methods of making a modulator of hemoglobin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160083343A1 (en) * 2013-03-15 2016-03-24 Global Blood Therapeutics, Inc Compounds and uses thereof for the modulation of hemoglobin
US20200157085A1 (en) * 2018-11-19 2020-05-21 Global Blood Therapeutics, Inc. Modulators of hemoglobin

Also Published As

Publication number Publication date
MX2023012156A (es) 2023-10-26
BR112023021606A2 (pt) 2023-12-19
ZA202309517B (en) 2024-06-26
EP4337659A1 (en) 2024-03-20
US20220363674A1 (en) 2022-11-17
US11851424B2 (en) 2023-12-26
AR126649A1 (es) 2023-11-01
US12473277B2 (en) 2025-11-18
AU2022273787B2 (en) 2025-04-03
JP2024520897A (ja) 2024-05-27
AU2022273787A1 (en) 2023-10-26
TW202311254A (zh) 2023-03-16
US20240076290A1 (en) 2024-03-07
CA3219786A1 (en) 2022-11-17
KR20240008356A (ko) 2024-01-18
WO2022241278A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
TWI588145B (zh) 降伊波加因鹽非溶劑化物
ES2750676T5 (en) Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
US12473277B2 (en) Solid forms of a modulator of hemoglobin
CN105431147A (zh) 2-羟基-6-((2-(1-异丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)苯甲醛的游离碱的结晶多晶型物
US10556896B2 (en) Crystalline forms of (3-Amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine
EP4438613A1 (en) Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof
HK40101540A (zh) 血红蛋白之调节剂的固体形式
CN112739679B (zh) 曲前列环素的特丁胺盐
AU2015392050B2 (en) Fumarate of pyridylamine compound and crystals thereof
WO2021001457A1 (en) Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
WO2025035486A1 (zh) 一种酪氨酸激酶抑制剂的可药用盐、结晶形式及其制备方法
CN116964065A (zh) 一种选择性NaV抑制剂的可药用盐、结晶形式及其制备方法
CN121175304A (zh) 胺基喹唑啉衍生物的盐
EA043230B1 (ru) Эрбуминовая соль трепростинила
CN105367602A (zh) 阿德福韦酯水杨酸共晶及其制备方法和组合物
NZ620948B2 (en) Noribogaine salt ansolvates
HK1224551A1 (en) Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101540

Country of ref document: HK